Herpes Zoster (Shingles) Pipeline Review, H2 2020: Therapeutic Analysis of 14 Companies & 15 Drug Profiles – ResearchAndMarkets.com
November 18, 2020DUBLIN–(BUSINESS WIRE)–The “Herpes Zoster (Shingles) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Herpes Zoster – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Herpes Zoster (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Herpes Zoster (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Herpes Zoster (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
Introduction
- Report Coverage
Herpes Zoster (Shingles) – Overview
Herpes Zoster (Shingles) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Herpes Zoster (Shingles) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Herpes Zoster (Shingles) – Companies Involved in Therapeutics Development
- Akshaya Bio Inc
- CanSino Biologics Inc
- Changchun Bcht Biotechnology Co Ltd
- CPL Biologicals Pvt Ltd
- DongKoo Bio & Pharma Co Ltd
- GC Pharma
- GeneOne Life Science Inc
- GlaxoSmithKline Plc
- NAL Pharmaceuticals Ltd
- NanoViricides Inc
- Shulov Innovative Science Ltd
- Vaccitech Ltd
- Vapogenix Inc
- XBiotech Inc
Herpes Zoster (Shingles) – Drug Profiles
B-1006 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
CRV-101 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
CSB-016 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Drug for Shingles – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
GLS-5100 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
herpes zoster vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
herpes zoster vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
interferon alfa-2b – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Monoclonal Antibodies for Shingles – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
NAL-3220 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
NVHHV-101 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecules for Inflammatory Pain – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
varicella zoster vaccine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
VTP-400 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
ZEP-3 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Herpes Zoster (Shingles) – Dormant Projects
Herpes Zoster (Shingles) – Discontinued Products
Herpes Zoster (Shingles) – Product Development Milestones
- Featured News & Press Releases
- Sep 15, 2020: Curevo Vaccine announces robust antibody response results of Phase I clinical trial of investigational vaccine for Shingles CRV-101
- Jul 23, 2020: CHMP recommended extension of indication for Shingrix
- May 14, 2020: NanoViricides provides update on drug candidate NV-HHV-101
- Mar 10, 2020: First QS-21 royalty payment due to Agenus is triggered
- Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101
- Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate
- Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
- Dec 03, 2019: NanoViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company
- Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND
- Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 – HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials
- Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
- Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101
- Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses
- Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
- Aug 26, 2019: NanoViricides advancing rapidly towards first IND
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/gh86u2
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900